How Has The Liquid Biopsy For Cancer Diagnostics Market Size Evolved Historically?
The liquid biopsy for cancer diagnostics market has seen considerable growth due to a variety of factors.
•The market size for cancer diagnostics using liquid biopsy has seen considerable growth recently. The market value is expected to rise from $9.23 billion in 2024 to $10.78 billion in 2025, with a compound annual growth rate (CAGR) of 16.8%.
Factors contributing to the growth during the historic period include advancements in genomic research, increased awareness of the advantages of liquid biopsy, higher cancer prevalence, a greater demand for non-invasive cancer testing, and the expansion of precision medicine initiatives.
What Will Be The Liquid Biopsy For Cancer Diagnostics Market Size In The Future?
The liquid biopsy for cancer diagnostics market is expected to maintain its strong growth trajectory in upcoming years.
• The market for liquid biopsy in cancer diagnostics is projected to experience significant expansion in the forthcoming years. The expected growth is to $19.32 billion in 2029 with an anticipated compound annual growth rate (CAGR) of 15.7%.
Multiple factors contribute to this anticipated growth during the forecast period, such as the incorporation of liquid biopsy into standard cancer diagnostics, the usage of liquid biopsy for early cancer detection, the expansion of cancer screening initiatives, a heightened focus on personalized medicine in oncology, and an increase in funding for liquid biopsy research. Key trends for the forecast period encompass the rise of multi-omics liquid biopsy approaches, the integration of artificial intelligence in liquid biopsy analysis, the broadening applications of liquid biopsy beyond oncology, the development of blood-based biomarkers for cancer and the customization of liquid biopsy testing for particular cancer types.
What Key Factors and Trends are Driving the Growth of the Liquid Biopsy For Cancer Diagnostics Market?
The escalating rate of cancer is anticipated to stimulate the expansion of the liquid biopsy for cancer diagnostics market. Cancer encompasses a vast group of diseases that can occur in practically any organ or tissue when rogue cells multiply rampantly, breach their typical boundaries, and spread to other organs or encroach on adjacent parts of the body. The upward trend in cancer necessitates diagnostic procedures such as early detection of cancer or tumor recurrence, patient-specific risk evaluation, and therapy monitoring. These enable liquid biopsy to capture the complete spectrum of the disease as tumor cells or their byproducts from all primary or metastasized tumor locations are released, offering comprehensive and contemporaneous data on tumor cell evolution, therapeutic targets, and therapy resistance mechanisms. For instance, as per the National Cancer Institute, a government agency based in the U.S., there were around 18.1 million people in the U.S. surviving with cancer in May 2024. This statistic is projected to surge to 22.5 million by 2032. It is anticipated that by 2040, the annual number of new cancer cases will touch 29.9 million, with cancer-related fatalities predicted to rise to 15.3 million. Therefore, the escalating rate of cancer is fuelling the expansion of the liquid biopsy for cancer diagnostics market.
What are the Market Segments in the Liquid Biopsy For Cancer Diagnostics Market?
The liquid biopsy for cancer diagnostics market covered in this report is segmented –
1) By Type: Product, Services
2) By Sample: Blood, Urine, Saliva
3) By Cancer: Lung Cancer, Breast Cancer, Colon Cancer, Other Cancers
4) By End-User: Hospitals, Diagnostic Centers, Other End-Users
Subsegments:
1) By Product: Circulating Tumor Cells (CTCs) Detection Kits, Circulating Tumor DNA (ctDNA) Detection Kits, Exosome Isolation Kits, Sample Collection Devices
2) By Services: Testing Services, Analytical Services, Bioinformatics Services
Pre-Book The Liquid Biopsy For Cancer Diagnostics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends are Shaping the Liquid Biopsy For Cancer Diagnostics Market?
The emergence of product innovations is becoming an increasingly prevalent trend in the liquid biopsy for cancer diagnostics market. With a focus on the invention of original products, major organizations in this field continually strive to fortify their market standing. For example, BostonGene, a biomedical software organization based in the US, introduced novel liquid biopsy solutions in June 2023. These solutions aim at identifying gene alterations of clinical significance. The expansion of the test portfolio will expedite the development of new assays, analytical instruments, and workflow strategies, ultimately offering patients precision medicine. This innovation merges a range of AI-powered molecular and immunological profiling techniques to inspect tumours, the surrounding environment, and host immune response. Further, it aids in immunotherapy treatments, provides insight on immune-related conditions of a patient, and oversees disease progression and response to the treatment.
Who Are the Key Players in the Liquid Biopsy For Cancer Diagnostics Market?
Major companies operating in the liquid biopsy for cancer diagnostics market include:
• F. Hoffman La Roche Ltd.
• Thermo Fisher Scientific Inc.
• Agilent Technologies Inc.
• Illumina Inc.
• The Menarini Group
• Bio-Rad Laboratories Inc.
• QIAGEN Inc.
• Exact Sciences Corporation
• Bio-Techne Corporation
• ArcherDX Inc.
• Neogenomics Laboratories Inc.
• Guardant Health Inc.
• Myriad Genetics Inc.
• Foundation Medicine Inc.
• Amoy Diagnostics Co. Ltd.
• Biocartis Group NV
• Biodesix Inc.
• MDx Health Inc.
• Sysmex Inostics Inc.
• Biocept Inc.
• Agena Bioscience Inc.
• Laboratory for Advanced Medicine (LAM) Inc.
• MiRXES Pte Ltd.
• Inivata Limited
• Resolution Bioscience Inc.
• SAGA Diagnostics AB
• NuProbe Inc.
• Personal Gemone Diagnostics Inc.
• Pathway Genomics Corporation
• Angle PLC
What are the Regional Insights into the Liquid Biopsy For Cancer Diagnostics Market?
North America was the largest region in the liquid biopsy for cancer diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the liquid biopsy for cancer diagnostics market report during the forecast period. The regions covered in the liquid biopsy for cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
